NCT01104675

Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer

A Phase 2 Study of Oral ENMD-2076 Administered to Patients With Platinum Resistant Ovarian Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 64 (actual)
• Sponsor: CASI Pharmaceuticals, Inc. · Industry
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether oral ENMD-2076 is effective in treatment of patients with platinum resistant ovarian, fallopian, or peritoneal cancer. Additional sites to be added.

Conditions

• Ovarian Cancer
• Fallopian Cancer
• Peritoneal Cancer

Interventions

Type	Name	Description
DRUG	ENMD-2076	275 mg (or 250 mg for BSA \< 1.65) per day in oral capsules in 28 day continuous cycles

Timeline

• Start date: 2010-04-01
• Primary completion: 2011-08-01
• Completion: 2012-12-01
• First posted: 2010-04-15
• Last updated: 2014-08-06

Locations

6 sites across 2 countries: United States, Canada